1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN, SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC WILKINSON WALSH + ESKOVITZ LLP Brian L. Stekloff (pro hac vice) ([email protected]) Rakesh Kilaru (pro hac vice) ([email protected]) 2001 M St. NW 10 th Floor Washington, DC 20036 Tel: 202-847-4030 Fax: 202-847-4005 HOLLINGSWORTH LLP Eric G. Lasker (pro hac vice) ([email protected]) 1350 I St. NW Washington, DC 20005 Tel: 202-898-5843 Fax: 202-682-1639 Attorneys for Defendant MONSANTO COMPANY ARNOLD & PORTER KAYE SCHOLER Pamela Yates (CA Bar No. 137440) ([email protected]) 777 South Figueroa St., 44th Floor Los Angeles, CA 90017 Tel: 213-243-4178 Fax: 213-243-4199 COVINGTON & BURLING LLP Michael X. Imbroscio (pro hac vice) ([email protected]) One City Center 850 10th St. NW Washington, DC 20001 Tel: 202-662-6000 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA IN RE: ROUNDUP PRODUCTS LIABILITY LITIGATION ) ) ) ) MDL No. 2741 Case No. 3:16-md-02741-VC MONSANTO COMPANY’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DR. CHADI NABHAN, DR. ANDREI SHUSTOV, AND DR. DENNIS WEISENBURGER ON DAUBERT GROUNDS Hearing dates: January 28, February 4 and 11, 2019 Time: 9:30AM Hardeman v. Monsanto Co., et al., 3:16-cv-0525-VC Stevick v. Monsanto Co., et al., 3:16-cv-2341-VC Gebeyehou v. Monsanto Co., et al., 3:16-cv-5813-VC ) ) ) ) ) ) ) ) ) ) ) Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 1 of 26
26
Embed
WILKINSON WALSH + ESKOVITZ LLP ARNOLD & PORTER KAYE …€¦ · Attorneys for Defendant MONSANTO COMPANY ARNOLD & PORTER KAYE SCHOLER Pamela Yates (CA Bar No. 137440) ([email protected])
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN, SHUSTOV AND WEISENBURGER
WILKINSON WALSH + ESKOVITZ LLP Brian L. Stekloff (pro hac vice) ([email protected]) Rakesh Kilaru (pro hac vice) ([email protected]) 2001 M St. NW 10th Floor Washington, DC 20036 Tel: 202-847-4030 Fax: 202-847-4005 HOLLINGSWORTH LLP Eric G. Lasker (pro hac vice) ([email protected]) 1350 I St. NW Washington, DC 20005 Tel: 202-898-5843 Fax: 202-682-1639 Attorneys for Defendant MONSANTO COMPANY
ARNOLD & PORTER KAYE SCHOLER Pamela Yates (CA Bar No. 137440) ([email protected]) 777 South Figueroa St., 44th Floor Los Angeles, CA 90017 Tel: 213-243-4178 Fax: 213-243-4199 COVINGTON & BURLING LLP Michael X. Imbroscio (pro hac vice) ([email protected]) One City Center 850 10th St. NW Washington, DC 20001 Tel: 202-662-6000
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
IN RE: ROUNDUP PRODUCTS LIABILITY LITIGATION
) ) ) )
MDL No. 2741 Case No. 3:16-md-02741-VC MONSANTO COMPANY’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DR. CHADI NABHAN, DR. ANDREI SHUSTOV, AND DR. DENNIS WEISENBURGER ON DAUBERT GROUNDS Hearing dates: January 28, February 4 and 11, 2019 Time: 9:30AM
Hardeman v. Monsanto Co., et al., 3:16-cv-0525-VC Stevick v. Monsanto Co., et al., 3:16-cv-2341-VC Gebeyehou v. Monsanto Co., et al., 3:16-cv-5813-VC
) ) ) ) ) ) ) ) ) ) )
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 1 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 - i -
MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN, SHUSTOV AND WEISENBURGER
I. The Three Experts Fail to Reliably Rule in Roundup as a Cause of Each Plaintiff’s NHL. ... 2
A. The Subset of Cherry-Picked Epidemiological Studies Provides an Insufficient Basis to Rule in Glyphosate as a Cause of Each Specific Plaintiff’s NHL. ........................................................................................................... 2
B. The Failure of These Experts to Do Anything Beyond Pointing to Their Preferred Studies Demonstrates the Unreliability of Their Approach. ........................ 5
II. Plaintiffs Fail To Rule-Out Other Potential Causes of Plaintiffs’ NHL. ................................. 7
A. Plaintiffs’ Experts Cannot Explain Why They Rule Out Non-Roundup Risk Factors With Arguments They Fail To Apply to Roundup. ................................ 8
B. Plaintiffs’ Experts Did Not Reliably Rule Out Idiopathic Causes. .............................. 9
C. Plaintiffs’ Experts Failed to Reliably Rule Out These Plaintiffs’ Specific Risk Factors. ............................................................................................................... 11
III. Plaintiffs’ Motion to Exclude Monsanto’s Expert Witnesses Is Meritless. ........................... 15
A. Plaintiffs’ Challenge to Monsanto’s Specific Causation Experts Misrepresents the Experts’ Methodology and Mischaracterizes the Specific Causation Inquiry. ........................................................................................ 16
B. Plaintiffs’ Challenges to Dr. Sullivan and Dr. Al-Khatib Go To Weight, Not Admissibility. ...................................................................................................... 19
C. Plaintiffs’ Challenge to Dr. Welch Would At Minimum Require Exclusion Of Their Own Regulatory Expert, Dr. Benbrook. ...................................................... 19
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 2 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 - ii -
MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN, SHUSTOV AND WEISENBURGER
Allen v. Penn. Eng’g Corp., 102 F.3d 194 (5th Cir. 1996) .................................................................................................... 6
Belisle v. BNSF Ry. Co., 697 F. Supp. 2d 1233 (D. Kan. 2010) .................................................................................... 19
Claar v. Burlington N. R.R. Co., 29 F.3d 499 (9th Cir. 1994) ...................................................................................................... 7
Clausen v. M/V New Carissa, 339 F.3d 1049 (9th Cir. 2003) .............................................................................. 13, 14, 16, 17
Cooper v. Takeda Pharm. Am., Inc., 191 Cal. Rptr. 3d 67 (Cal. Ct. App. 2015) ....................................................................... 3, 5, 9
Gen. Elec. Co. v. Joiner, 522 U.S. 136 (1997) ................................................................................................................. 6
In re Bextra & Celebrex Mktg. Sales Practices & Prod. Liab. Litig., 524 F. Supp. 2d 1166 (N.D. Cal. 2007) ............................................................................... 4, 6
In re Diet Drugs Prod. Liab. Litig., 890 F. Supp. 2d 552 (E.D. Pa. 2012) ..................................................................................... 11
In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices and Prod. Liab. Litig., 892 F.3d 624 (4th Cir. 2018) .................................................................................... 2, 8, 11, 15
In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices and Prod. Liab. Litig., 150 F. Supp. 3d 644 (D. S.C. 2015) ....................................................................................... 17
In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices and Prod. Liab. Litig., 185 F. Supp. 3d 786 (D.S.C. 2016) .................................................................................. 11, 14
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 3 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 - iii -
MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN, SHUSTOV AND WEISENBURGER
In re Mirena IUD Prod. Liab. Litig., 169 F. Supp. 3d 396 (S.D.N.Y. 2016) .............................................................................. 16, 17
In re Roundup Prods. Liab. Litig., 2018 WL 3368534 (N.D. Cal. July 10, 2018) .............................................................. 2, 3, 4, 8
In re Silicone Gel Breast Implants Prod. Liab Litig., 318 F. Supp. 2d 879 (C.D. Cal. 2004) ..................................................................................... 4
In re Zimmer Nexgen Knee Implant Prod. Liab. Litig., 218 F. Supp. 3d 700 (N.D. Ill. 2016) ..................................................................................... 17
Interwoven, Inc. v. Vertical Computer Sys., No. CV 10-04645 RS, 2013 WL 3786633 (N.D. Cal. July 18, 2013) ................................... 19
Lust By & Through Lust v. Merrell Dow Pharm., Inc., 89 F.3d 594 (9th Cir. 1996) ...................................................................................................... 5
Reference Manual on Scientific Evidence (Federal Judicial Center 2d ed. 2000) ............................... 4
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 4 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 1 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
INTRODUCTION
The task that Plaintiffs have set for themselves is hardly “daunting.” They argue not only that
their experts have reliably ruled in Roundup as a cause of their particular NHL, but that it would
actually be an error for an expert to reach any other conclusion, simply because this Court found that
Plaintiffs “barely” surmounted the broader question of whether Roundup could conceivably cause
cancer at the highest doses to which humans might be exposed. Plaintiffs’ position excuses them
from answering the question that the first prong of a valid specific causation differential diagnosis
poses: What is it about a particular Plaintiff that allows the expert to reliably rule in Roundup as a
cause of his or her NHL? In their experts’ collective view, as long as a minimal exposure threshold
is reached, Roundup automatically becomes a substantial factor in causing a Plaintiff’s NHL.
Plaintiffs then treat the ruling out prong as a largely illusory exercise. Their experts have offered
nothing more than say-so in dismissing other, well-recognized risk factors for Plaintiffs’ NHL, and
in fact violate basic tenets of logic and scientific consistency in dismissing other causes based on
reasoning that if faithfully employed would apply equally to Roundup. Recognizing that this method
is indefensible, Plaintiffs seek to eviscerate the ruling-out requirement, claiming that as a matter of
law, other causes, including unknown causes, need not really be excluded, or at least not definitively
so. Even if such other causes might exist, they argue, that does not excuse Roundup as an equal
contributing cause.
Plaintiffs are wrong. The upshot of their argument is that everyone with a minimal level of
Roundup exposure who later develops NHL has established causation, regardless of other risk factors
or the fact that the vast majority of NHL cases have no known cause. That’s a tautology, not a
differential diagnosis. But Daubert requires more. Here, it requires a daunting, Plaintiff-specific
exercise grounded in scientific methodology that Plaintiffs’ experts have not even attempted to
provide. Because Plaintiffs’ experts have failed to apply the proper rigorous analysis at both stages
of their differential diagnosis, Plaintiffs have not met their burden of establishing the reliability of
their experts under Rule 702.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 5 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 2 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
ARGUMENT
I. The Three Experts Fail to Reliably Rule in Roundup as a Cause of Each Plaintiff’s NHL.
A. The Subset of Cherry-Picked Epidemiological Studies Provides an Insufficient Basis to Rule in Glyphosate as a Cause of Each Specific Plaintiff’s NHL.
Plaintiffs’ approach fundamentally conflates the general and specific causation inquiries. The
question at the general cause phase was whether Roundup can cause NHL at the highest dose humans
could possibly experience. See In re Roundup Prods. Liab. Litig., 2018 WL 3368534, at *5 (N.D.
Cal. July 10, 2018). (“Picture, for instance, a professional gardener who has applied Roundup without
using protective equipment several times per week, many hours per day, for decades.”). Here, that
inquiry is materially different, and focuses on individual Plaintiff-specific facts and circumstances.
Plaintiffs’ experts cannot mechanically rule in Roundup for particular Plaintiffs simply because the
Court concluded that Plaintiffs’ proffered studies provided a (barely) sufficient basis to create a jury
question for the conceivably most at-risk person. See, e.g., In re Lipitor (Atorvastatin Calcium) Mktg.,
Sales Practices and Prod. Liab. Litig., 892 F.3d 624, 644 (4th Cir. 2018) (“That Lipitor may cause
an increased risk of diabetes notwithstanding certain other risk factors is insufficient to conclude that
the drug was a substantial contributing factor in an individual patient. To hold otherwise would
obviate the need for any specific causation evidence at all.”). Yet Plaintiffs have conceded that all
their experts offer to rule in Roundup is a subset of cherry-picked studies used at the general causation
phase—without regard to the individual facts of a given Plaintiff and without recognition of the
different epidemiological burden at the specific causation stage.
Where, as here, experts rely solely on epidemiological studies to meet their specific causation
ruling in burden, those studies must meet certain reliability standards. But the two main studies all
of Plaintiffs’ experts rely upon—McDuffie 2001 and Eriksson 2008—do not provide a reliable basis
for a specific causation opinion because they fail to control for other pesticides or other “statistically
significant medical variables.” Compare Ex. 1, Helen H. McDuffie et al., Non-Hodgkin's Lymphoma
and Specific Pesticide Exposures in Men: Cross-Canada Study of Pesticides and Health, 10 CANCER
EPIDEMIOL, BIOMARKERS & PREVENTION 1155, 1158 (2001), with id. at 1161. This Court has
explained that this failure to control for confounding variables “can skew the results,” rendering the
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 6 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 3 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
studies unreliable. In re Roundup, 2018 WL 3368534, at *8. To be sure, courts have admitted studies
that did not control for all confounding variables. See Cooper v. Takeda Pharm. Am., Inc., 191 Cal.
Rptr. 3d 67, 94 (Cal. Ct. App. 2015). But in Cooper, the Azoulay study authors acknowledged the
unaccounted-for variables and concluded the failure to control for them would not have “affected the
internal validity of the study” because it was “unlikely that these variables were differentially
distributed between ever users of [the at-issue product] and ever users of other [substitute goods].”
Id. Cooper also noted the Azoulay study’s other remarkable strengths. Id. The authors of McDuffie
2001 and Eriksson 2008 came to no such conclusion regarding the failure to control for other
pesticides. This omission is fatal.
Plaintiffs now highlight De Roos 2003, even though the experts themselves place little
emphasis on that study because it does not show a dose-response and make no effort to account for
the disparate odds ratios in the different analyses. Ex. 2, A.J. De Roos et al., Integrative Assessment
of Multiple Pesticides as Risk Factors for Non-Hodgkin’s Lymphoma Among Men, 60 OCCUP &
ENVIRON MEDI 1, 5 (2003) (hierarchical regression analysis yielded an odds ratio for glyphosate, after
controlling for other pesticides, of 1.6 that was not statistically significant); see also In re Roundup,
2018 WL 3368534, at *30 (excluding Dr. Neugut as unreliable after he failed to explain the difference
between De Roos’s two regressions). Plaintiffs also ignore that the De Roos data was ultimately
pooled into NAPP, and when properly adjusted, showed no increased risk. See Ex. 3, Manisha Pahwa
et al., An Evaluation of Glyphosate Use and the Risks of Non-Hodgkin Lymphoma Major Histological
Sub-Types in the North American Pooled Project (Aug. 31, 2015); In re Roundup, 2018 WL 3368534,
at *10 (NAPP “overall odds ratio for glyphosate use of 1.13 (0.84, 1.51), when adjusted for use of
three other pesticides and several other potential confounders. . . . When proxy respondents were
removed from the data, the odds ratio dropped to 0.95 (0.69, 1.32).”). Plaintiffs’ selective reliance
on what they perceive to be the favorable component of De Roos only reinforces the outcome-
determinative nature of their experts’ methodology, simply picking and choosing results that support
their position while ignoring the larger scientific landscape.
That Plaintiffs go to such lengths in this cherry-picking exercise only reinforces their implicit
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 7 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 4 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
recognition of the problem they have meeting the threshold California requirement: for an expert to
rule in a cause at the specific causation stage through a differential diagnosis based on epidemiology,
which is what all three experts do here, that epidemiology must show at least a doubling of the risk
to provide a proper foundation for that opinion. In re Bextra & Celebrex Mktg. Sales Practices &
Prod. Liab. Litig., 524 F. Supp. 2d 1166, 1172 (N.D. Cal. 2007). This heightened standard highlights
the difference between the general and specific causation phases: only when “a relative risk that is
greater than 2.0” can a jury conclude “that the agent was more likely than not responsible for a
particular individual’s disease.” In re Silicone Gel Breast Implants Prod. Liab Litig., 318 F. Supp.
Dep. at 54:3–15; 76:19–22, ECF No. 2420-14. Plaintiffs also cite (at 21) Hall v. Conoco for the
unremarkable proposition that an expert need not eliminate every “conceivable” cause. 886 F.3d
1308, 1314 (10th Cir. 2018). But they ignore the core holding affirming the exclusion of the expert’s
differential diagnosis because the expert failed to reliably rule out idiopathic causes: “Because
idiopathy accounts for more than half of the cases of acute myeloid leukemia, a differential diagnosis
could be considered inherently unreliable here.” Id. at 1315.1
C. Plaintiffs’ Experts Failed to Reliably Rule Out These Plaintiffs’ Specific Risk Factors.
Plaintiffs’ specific defense of their experts’ ruling out of the risk factors present for these
Plaintiffs (at 21–26) betrays the central outcome-driven nature of their experts’ methodology. Resort
to vacuous generalities like “clinical judgment and extensive knowledge” (at 21) in purportedly ruling
out other risk factors does not serve as some magic wand to bless an otherwise unscientific exercise.
See In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices and Prod. Liab. Litig., 185 F. Supp.
3d 786, 805–06 (D.S.C. 2016) (excluding expert who noted that the plaintiff’s age put her at an
increased risk of diabetes, but summarily concluded it was “not clinically significant”: “clinical
judgment is nothing more than unacceptable ipse dixit testimony”), aff’d, 892 F.3d at 644 (“Dr.
Murphy did consider (and purportedly ruled out) several other risk factors, including Ms.
Hempstead’s family history, race, body mass index (‘BMI’), and age. But her analysis of those
factors—and, more importantly, her reasons for rejecting them as the likely cause of Ms. Hempstead’s
disease—fell short.”). At bottom, Plaintiffs all but concede this issue, instead arguing (at 21–22) that
ruling out the other risk factors does not really matter in the end: even if the other causes cannot be
ruled out, as long as Roundup is one of those factors, that should be enough under Daubert. That
simply cannot be the law, for taken to its logical conclusion, there would be no need for specific
causation evidence at all. See, e.g., In re Lipitor, 185 F. Supp. 3d at 799 (expert “cannot simply opine
1 Plaintiffs’ citation to dicta in In re Diet Drugs, 890 F. Supp. 2d 552, 557 (E.D. Pa. 2012) hardly helps them because the court in that case was simply interpreting the terms of a settlement agreement and concluded that “evidence excluding idiopathic or unknown causes of PPH is not required under the plain meaning of the Settlement Agreement.” Id. at 558.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 15 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 12 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
that all present risk factors are ‘substantial contributing factors’”); Guinn v. AstraZeneca Pharm. LP,
602 F.3d 1245, 1255 (11th Cir. 2010) (“An expert, however, cannot merely conclude that all risk
factors for a disease are substantial contributing factors in its development.”).
1.
2.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 16 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 13 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
3.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 17 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 14 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
4.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 18 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 15 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
5.
III. Plaintiffs’ Motion to Exclude Monsanto’s Expert Witnesses Is Meritless.
To help the jury address whether Roundup caused Plaintiffs’ NHL in particular, Monsanto
retained leading clinicians with experience and specialized training in treating patients with cancer.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 19 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 16 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
These experts span a variety of fields: hematology/oncology (Dr. Levine, at City of Hope, and Celeste
Bello, at the Moffitt Cancer Center); oncology (Dr. Michael Grossbard, at New York University);
pathology (Lawrence Zuckerberg, at Massachusetts General Hospital, and Christian Steidl, at the
University of British Columbia); and neuroradiology (Juan Pablo Villablanca, at UCLA). They each
brought their clinical perspective to bear in conducting a differential diagnosis of one or several
Plaintiffs to determine if there is an identifiable cause for their NHL (recognizing that NHL is
idiopathic in the vast majority of cases), including potentially Roundup.
Without bothering to depose any of these experts, Plaintiffs launch a series of broadsides that
are both devoid of supporting authority and seemingly calculated only to shift attention away from
their own experts. Plaintiffs’ attacks seek to blur the task of Plaintiffs’ experts—to come forward
with reliable, admissible evidence supporting specific causation in the face of a dubious scientific
connection—with the role of a defense expert, whose proper focus can be critiquing the Plaintiffs’
experts unscientific efforts and explaining why the available science is inadequate to demonstrate
causation. See, e.g., In re Mirena IUD Prod. Liab. Litig., 169 F. Supp. 3d 396, 418–19 (S.D.N.Y.
2016), aff’d, 2017 WL 4785947 (2d Cir. Oct. 24, 2017) (“pointing to the absence of convincing
studies or the weaknesses of studies on which Plaintiffs rely, and evaluating them in light of their
clinical experience, training and research, is . . . a logical and valid approach.”).
A. Plaintiffs’ Challenge to Monsanto’s Specific Causation Experts Misrepresents the Experts’ Methodology and Mischaracterizes the Specific Causation Inquiry.
There is nothing improper about the way Monsanto’s experts conducted their differential
diagnoses here. To take just one example, Dr. Grossbard conducted an extensive review of Mr.
Hardeman’s medical records, see Grossbard Hardeman Rep. at 3–4, ECF No. 2481-1; explained the
nature of NHL, the relevant recognized risk factors for it, and the literature supporting those risk
factors, id. at 5–7; and then analyzed and considered several epidemiological studies in assessing
whether Roundup could be “ruled in” as an additional risk factor that somehow rises to an identifiable
cause of Mr. Hardeman’s cancer, id. at 7–8; see Clausen , 339 F.3d at 1057 (first step of diagnosis is
“to compile a comprehensive list of hypotheses that might explain the set of salient clinical findings
under consideration”). In that last step, Dr. Grossbard considered not just the studies Plaintiffs’
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 20 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 17 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
experts highlight (or the odds ratios unadjusted for other pesticides in those studies), but the 2018
NCI study, which is the largest epidemiological analysis of whether there is any connection between
glyphosate and NHL. Ultimately, relying on his clinical judgment and assessment of the medical
records and the literature, and after considering all the possible risk factors,
Those are the elements of a valid differential diagnosis. Defendants’ experts addressed in
depth the specific other risk factors present for the individual Plaintiffs, as well as the established
medical literature surrounding those risk factors. That is the critical distinction between the
excludable, results-oriented methodology Plaintiffs’ experts apply and the reliable methods
Defendants’ experts have employed.2
Plaintiffs (at 28) complain that Monsanto’s experts are offering improper general causation
opinions. Not so. As even a cursory review of the experts’ reports reveals, Defendants’ specific
causation experts focus on the individual circumstances of the Plaintiffs, not previously-discussed
2 Indeed, the authorities Plaintiffs cite all demonstrate that Plaintiff’s experts should be excluded. Norris v. Baxter Healthcare Corp., 397 F.3d 878, 887 (10th Cir. 2005) (specific causation opinions based purely on say-so about clinical experience excluded and have “not gained acceptance in the relevant scientific community.”); In re Zimmer Nexgen Knee Implant Prod. Liab. Litig., 218 F. Supp. 3d 700, 714 (N.D. Ill. 2016) (excluding an opinion that consisted of nothing more than a “bottom line”); In re Mirena IUD Products Liability Litigation, 169 F. Supp. 3d 396, 436 (S.D.N.Y. 2016) (excluding the specific causation testimony of an expert who like Dr. Nabhan here had no reliable opinions on general causation).
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 21 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 18 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
studies of Roundup. See, e.g., Grossbard Hardeman Rep. at 3–7, ECF No. 2481-1; Levine Hardeman
Rep. at 12–19, ECF No. 2479-18. To be sure, Defendants’ experts did provide some analysis of the
epidemiological studies regarding Roundup—but they did so in order to fairly consider the
circumstances of each Plaintiff and to put into perspective why they do not believe Roundup or
glyphosate are established risk factors that must be ruled out. See, e.g., Ex. 4, Case Management
Conference Tr. at 28:20–29:7, Dec. 5, 2018 (“And I was assuming that it would be impossible to have
a strict delineation between the concept of general causation and the concept of specific causation.);
see also Pretrial Order No. 7 at 8, ECF No. 103 (“This Order shall not preclude the parties from
designating additional experts who may offer opinions relating to general or specific causation if this
MDL proceeds beyond the general-causation phase.”).
Plaintiffs next accuse Monsanto’s experts (at 30) of conducting only a “superficial review” of
the existing epidemiology. But it is Plaintiffs’ experts who limit their analysis to a “superficial
review” of the cherry-picked subset of epidemiological studies that support their pre-ordained
conclusions, whereas Defendants’ experts by contrast surveyed more of the epidemiology, including
both the studies Plaintiffs’ experts favor as well as other relevant papers, including broad-ranging
2018 NCI study.
Plaintiffs’ final suggestion (at 34)—that Defendants’ experts should actually be excluded
because they do not consider Roundup to be a risk factor for any of these Plaintiffs—would stand
Daubert on its head. Plaintiffs effectively argue that Roundup must be deemed to be a substantial
factor in every case, with the burden on Defendants to disprove that point based on the medical
records of a specific Plaintiff. But the Court’s prior Daubert ruling concluded only that there is a jury
question as to whether Roundup could conceivably cause cancer in some people. It did not ordain,
as an undisputed point of scientific fact, that Roundup is actually a risk factor for any particular
Plaintiff’s NHL—and indeed, the Court rejected Plaintiffs’ Daubert challenges essentially seeking to
advance that point. Ultimately, Defendants’ experts carefully considered the Plaintiffs’ medical
records, the nature of NHL, the recognized risk factors for NHL and the literature surrounding them,
and the best available scientific evidence regarding the possibility that Roundup may also be a risk
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 22 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 19 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
factor. They then applied their real-world experience to that evidence and concluded that Roundup
did not constitute a substantial factor in the Plaintiffs’ NHL.
B. Plaintiffs’ Challenges to Dr. Sullivan and Dr. Al-Khatib Go To Weight, Not Admissibility.
Plaintiffs’ challenge to Dr. Sullivan and Dr. Al-Khatib is not a Daubert challenge at all. The
Daubert inquiry fundamentally is about the methods an expert employs, not their results. See Belisle
v. BNSF Ry. Co., 697 F. Supp. 2d 1233, 1244 (D. Kan. 2010). But Plaintiffs do not challenge these
experts’ methodology at all. Their objection is instead to the facts the experts plugged into their
analysis. For example, they complain that Dr. Al-Khatib may not have examined the entire property,
and speculate that the condition of the property to which the experts applied their exposure
methodology may have changed since the time the Hardemans vacated it. Pls.’ Resp. at 38–39. That
is a quintessential challenge to weight, not admissibility. Plaintiffs cite no authority supporting their
arguments for exclusion. On the contrary, both experts explain that they interviewed the current
owner of the property and concluded that there were not material changes. And Plaintiffs themselves
cite authority confirming that experts can “rely on hearsay evidence in coming to their conclusions,
so long as an expert in the field would reasonably rely on that information”—and when experts do
so, “[i]t is for a jury to decide” whether the expert’s reliance was reasonable. Interwoven, Inc. v.
Vertical Computer Sys., No. CV 10-04645 RS, 2013 WL 3786633, at *7 (N.D. Cal. July 18, 2013).
C. Plaintiffs’ Challenge to Dr. Welch Would At Minimum Require Exclusion Of Their Own Regulatory Expert, Dr. Benbrook.
Plaintiffs’ complaints about Dr. Welch underscore why the testimony she seeks to offer is
within the proper purview of a regulatory expert—unlike the testimony of Plaintiffs’ expert, Dr.
Benbrook. For example, Plaintiffs highlight that Dr. Welch did not apply “the weight of the evidence
methodology while at EPA.” Pls.’ Resp. at 40. But the relevant point is that Dr. Welch actually
worked at EPA, unlike Dr. Benbrook—who purports to comment not only on EPA’s process but also
its motives despite never working at any regulatory body or any company subject to EPA regulations.
See Def.’s Mot. to Exclude Testimony of Dr. Charles Benbrook at 10, ECF No. 2417. Likewise,
Plaintiffs complain that Dr. Welch offers “a historical narrative of EPA’s treatment of glyphosate”
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 23 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 20 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
without any further opinions, Pls.’ Resp. at. 39, but the types of opinions Dr. Benbrook offers, about
the motives and interests of third parties, is improper. See Def.’s Mot. to Exclude Testimony of Dr.
Charles Benbrook at 11, ECF No. 2417. In short, Dr. Welch’s properly limited, experience-based
assessment of EPA’s actions regarding glyphosate is the only regulatory testimony that should be
admitted in this case.
Case 3:16-md-02741-VC Document 2525 Filed 01/18/19 Page 24 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
- 21 - MONSANTO’S REPLY BRIEF IN SUPPORT OF MOTION TO EXCLUDE TESTIMONY OF DRS. NABHAN,
SHUSTOV AND WEISENBURGER 3:16-md-02741-VC & 3:16-cv-0525-VC, 3:16-cv-2341-VC, 3:16-cv-5813-VC
DATED: January 18, 2019 Respectfully submitted, /s/ Brian L. Stekloff___________ Brian L. Stekloff (pro hac vice) ([email protected]) Rakesh Kilaru (pro hac vice) ([email protected]) WILKINSON WALSH + ESKOVITZ LLP 2001 M St. NW, 10th Floor Washington, DC 20036 Tel: 202-847-4030 Fax: 202-847-4005